Promo Video NorTrials

Contributors:

Ingvild Kjerkhol, Minister of Health and Care Services
Terje Rootwelt, Head of the NorTrials board
Leif Rune Skymoen, Head of the Association of the Pharmaceutical Industry in Norway (LMI)
Catherine Capdeville, Business Policy Director, Melanor
Signe Øien Fretland, Head of NorTrials Coordinating Unit
Peder L. Myhre, Head of NorTrials Cardiovascular
Åslaug Helland, Head of NorTrials Cancer
Thomas Langø, Head of NorTrials Medical Devices
Ingrid Stenstadvold Ross, Secretary General, the Norwegian Cancer Society

Transcript:

Ingvild Kjerkhol: NorTrials is Norway's initiative to increase the volume of clinical trials initiated by the pharmaceutical and medical device industry in our hospitals. We want to integrate clinical trials as part of the standard of care. This public-private partnership will benefit the industry, the healthcare sector and personnel and ultimately the patients.

Terje Rootwelt (TR): Clinical trials provide early access to innovative treatment and technical solutions under development and builds competence in the healthcare system.

Leif Rune Skymoen: The NorTrials partnership aims to build a closer collaboration between the private healthcare industry and the public healthcare system.

Catherine Capdeville: NorTrials builds on the efficiencies and solid structure of the healthcare system in Norway, where the society has a high level of trust in the authorities, and a willingness to participate in clinical trials. A unique personal identifier for all citizens makes long-term follow-up easier.

Signe Øien Fretland: NorTrials provides a national entry point for the industry, covering all therapeutic areas and all Norwegian hospitals. NorTrials will facilitate the contact between the industry and the healthcare system and ensure a timely response.

Peder Langeland Myhre: NorTrials has established six centers with high expertise within five defined therapeutic areas and one center dedicated to medical devices. The centers were selected in collaboration with industry.

Åslaug Helland: The centers are responsible for building national networks within their fields of expertise, to ensure access to clinical trials for patients throughout the country as well as efficient trial enrollment.

Thomas Langø: The centers will promote Norway to the pharmaceutical and medical device industry as a preferred country for performing clinical trials within their areas.

Ingrid Stenstadvold Ross: The ultimate goal for NorTrials is to provide better access to investigational treatment through clinical trials for patients throughout Norway, and to contribute to continuous improvement of patient treatment.

Terje Rootwelt: Clinical trials benefit the patients, the healthcare system and the entire society.

All: Welcome to Norway!